头孢菌素类铁载体头孢地尔的活性对来自北美和欧洲的近期临床相关革兰氏阴性杆菌的收集，包括耐碳青霉烯类分离株（SIDERO-WT-2014 研究）。
Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).
机构信息
International Health Management Associates, Inc., Schaumburg, Illinois, USA
Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan.
出版信息
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00093-17. Print 2017 Sep.
Cefiderocol (formerly S-649266) is an investigational siderophore cephalosporin. Iron-depleted cation-adjusted Mueller-Hinton broth (ID-CAMHB) was prepared according to the Clinical and Laboratory Standards Institute (CLSI) protocol and used to perform broth microdilution testing of cefiderocol against a 2014-2015 collection of clinical isolates of Gram-negative bacilli from North America ( = 4,239) and Europe ( = 4,966). The concentrations of cefiderocol inhibiting 90% of isolates tested (MICs) were 0.5 μg/ml (North America; = 3,007) and 1 μg/ml (Europe; = 3,080) for all isolates of ; 1 μg/ml (North America; = 30) and 4 μg/ml (Europe; = 139) for meropenem-nonsusceptible (MIC ≥ 2 μg/ml) isolates of ; 0.5 μg/ml for both North American ( = 765) and European ( = 765) isolates of ; 0.5 μg/ml (North America; = 151) and 1 μg/ml (Europe; = 202) for meropenem-nonsusceptible (MIC ≥ 4 μg/ml) isolates of ; 1 μg/ml for both North American ( = 309) and European ( = 839) isolates of all strains as well as for both North American ( = 173) and European ( = 595) isolates of meropenem-nonsusceptible ; and 0.5μg/ml (North America; = 152) and 0.25 μg/ml (Europe; = 276) for isolates of MICs of cefiderocol were ≤4 μg/ml for 99.9% (6,078/6,087) of all , 97.0% (164/169) of meropenem-nonsusceptible , 99.9% (1,529/1,530) of all isolates, 100% (353/353) of meropenem-nonsusceptible isolates, 97.6% (1,120/1,148) of all isolates, 96.9% (744/768) of meropenem-nonsusceptible isolates, 100% of isolates of (428/428) and 93.8% of isolates of (11/12). We conclude that cefiderocol demonstrated potent activity against a recent collection of clinical isolates of commonly encountered Gram-negative bacilli, including carbapenem-nonsusceptible isolates.
头孢他啶（S-649266）是一种新型的铁载体头孢菌素。根据临床和实验室标准协会（CLSI）的方案，制备缺铁阳离子调整 Mueller-Hinton 肉汤（ID-CAMHB），并用于检测头孢他啶对来自北美（= 4239）和欧洲（= 4966）的 2014-2015 年临床分离的革兰氏阴性菌的肉汤微量稀释试验。抑制 90%受试分离株的头孢他啶浓度（MICs）分别为 0.5μg/ml（北美；= 3007）和 1μg/ml（欧洲；= 3080），对所有 分离株有效；1μg/ml（北美；= 30）和 4μg/ml（欧洲；= 139），对美罗培南不敏感（MIC≥2μg/ml）的 分离株有效；0.5μg/ml，对北美（= 765）和欧洲（= 765）的 分离株均有效；0.5μg/ml（北美；= 151）和 1μg/ml（欧洲；= 202），对美罗培南不敏感（MIC≥4μg/ml）的 分离株有效；1μg/ml，对北美（= 309）和欧洲（= 839）的所有 分离株均有效，对北美（= 173）和欧洲（= 595）的美罗培南不敏感的 分离株均有效；0.5μg/ml（北美；= 152）和 0.25μg/ml（欧洲；= 276），对 MICs 为头孢他啶的分离株的 MICs≤4μg/ml 的分离株为 99.9%（6078/6087），美罗培南不敏感的分离株为 97.0%（164/169），所有 分离株为 99.9%（1529/1530），美罗培南不敏感的 分离株为 100%（353/353），所有 分离株为 97.6%（1120/1148），美罗培南不敏感的 分离株为 96.9%（744/768）， 分离株为 100%（428/428）， 分离株为 93.8%（11/12）。我们得出结论，头孢他啶对最近收集的临床分离的常见革兰氏阴性菌，包括耐碳青霉烯的分离株，表现出强大的抗菌活性。
Zotero 插件